ERBB2 and metastatic neoplasm: Despite these limitations, the clear conclusion of this study is that progressive disease in HER-2 negative women with metastatic breast cancer is associated with clinically relevant worsening of symptoms across multiple domains, and that symptom severity may partly depend on the organ systems affected by metastatic disease.